BioAffinity Technologies Enhances Lung Cancer Detection Access for Veterans with CyPath® Lung Tool
- BioAffinity Technologies showcases CyPath® Lung at the NAVREF meeting, enhancing lung cancer detection access for veterans.
- The Veterans Health Administration incorporates CyPath® Lung into its system, serving 1,380 facilities and 9.1 million veterans.
- BioAffinity aims to improve veterans' health outcomes through innovative noninvasive cancer detection and strategic partnerships.
BioAffinity Technologies Expands Access to Lung Cancer Diagnostic Tool for Veterans
BioAffinity Technologies, Inc., a biotechnology firm focused on noninvasive early-stage cancer detection, prepares to showcase its innovative CyPath® Lung diagnostic tool at the National Association of Veterans’ Research and Education Foundations (NAVREF) meeting. This presentation comes on the heels of the Veterans Health Administration (VHA) incorporating CyPath® Lung into its Federal Supply System (FSS), which services 1,380 healthcare facilities and approximately 9.1 million veterans each year. The integration provides access to over 170 medical centers and more than 1,000 outpatient sites across the United States, marking a significant advancement in the company’s efforts to enhance cancer detection among veteran populations.
The inclusion of CyPath® Lung in the FSS underscores a pivotal moment for bioAffinity Technologies, as it broadens the availability of the diagnostic tool to a vast network of healthcare providers. Maria Zannes, President and CEO of bioAffinity, expresses her gratitude to NAVREF for their role in raising awareness of CyPath® Lung among Veterans Affairs (VA) stakeholders and industry partners. Zannes emphasizes the importance of collaboration with the VA's National Acquisition Center, highlighting how such partnerships can lead to improved healthcare delivery for veterans. This collaborative effort is vital, especially considering that veterans face heightened risks for lung cancer due to age, smoking habits, and environmental exposures during military service.
NAVREF's CEO, Rashi Romanoff, commends the partnership between bioAffinity and the VHA, recognizing the crucial role of public-private collaborations in advancing veterans' health outcomes through innovative diagnostic solutions. The organization's commitment to promoting research and education for VA-affiliated nonprofits aligns with bioAffinity's goals. Initiatives like the Lung Precision Oncology Program aim to enhance the detection and treatment of lung cancer, which is particularly relevant given the increased prevalence of the disease among veterans. Through these concerted efforts, bioAffinity Technologies positions itself as a key player in transforming lung cancer diagnostics and improving the quality of care provided to veterans.
In addition to the strategic partnership with the VHA, bioAffinity Technologies continues to explore opportunities to leverage its expertise in noninvasive diagnostics. The company aims to further develop its product offerings in oncology and expand its reach within the healthcare sector. The NAVREF meeting serves as a platform for bioAffinity to connect with potential collaborators and stakeholders interested in advancing cancer detection technologies.
As bioAffinity Technologies moves forward with its initiatives, the emphasis remains on improving health outcomes for veterans through innovative solutions. The company’s commitment to enhancing early-stage cancer detection aligns with broader efforts to ensure that those who have served the nation receive the comprehensive healthcare they deserve.
